Clinical and Bacterial Risk Factors for Mortality in Children with Carbapenem-resistant Enterobacteriaceae Bloodstream Infections in India

Pediatric Infectious Disease Journal

Volumn 36, Issue 6, 2017, Pages e161-e166

  Nabarro, Laura E B ^a,b   Shankar, Chaitra ^a   Pragasam, Agila K ^a   Mathew, Georgekutty ^a   Jeyaseelan, Visali ^a   Veeraraghavan, Balaji ^a   Verghese, Valsan P ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

bacteremia; carbapenem resistant; children; colistin; meropenem

Indexed keywords

CARBAPENEMASE; COLISTIN; MEROPENEM; TIGECYCLINE; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ARTICLE; BACTERIAL RISK FACTOR; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE BLOODSTREAM INFECTION; CHILD; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CLINICAL RISK FACTOR; ESCHERICHIA COLI; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INDIA; KLEBSIELLA PNEUMONIAE; MALE; MEROPENEM RESISTANT ESCHERICHIA COLI; MEROPENEM RESISTANT KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; ANTIBIOTIC RESISTANCE; BACTEREMIA; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; INFANT; MICROBIOLOGY; MORTALITY; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INDIA; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85007153943     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001499     Document Type: Article

References (45)

1. Tängdén T Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015; 277: 501 512.
2. Falagas ME Tansarli GS Karageorgopoulos DE. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014; 20: 1170 1175.
3. Guh AY Bulens SN Mu Y. Epidemiology of carbapenem-resistant enterobacteriaceae in 7 US communities, 2012-2013. JAMA. 2015; 314: 1479 1487.
4. Caselli D Cesaro S Fagioli F; Infectious Diseases Study Group of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy. Infect Dis (Lond). 2016; 48: 152 155.
5. Logan LK Renschler JP Gandra S. Carbapenem-resistant enterobacteriaceae in children, United States, 1999-2012. Emerg Infect Dis. 2015; 21: 2014 2021.
6. Díaz A Marín DC Honeysberg MT. Clinical characteristics of carbapenem resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia. Pediatr Infect Dis J. 2015. doi: 10.1097/INF.0000000000000987.
7. Muhammad Usman Qamar FN Timothy W Rubina K. Prevalence and clinical burden of NDM positive infections in pediatric and neonatal patients in Pakistan. Pediatr Infect Dis J. 2015; 34: 452 454.
8. Drew RJ Turton JF Hill RL. Emergence of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospital. J Hosp Infect. 2013; 84: 300 304.
9. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. Clin Infect Dis. 2012; 55: 852 859.
10. Cheng Chao LY-X Zhang Zhi-Jie. Risk factors for multidrug-resistant Klebsiella pneumoniae sepsis in children. Chin J Contemp Pediatr. 2015; 17: 932 936.
11. Tumbarello M Viale P Viscoli C. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55: 943 950.
12. Tumbarello M Viale P Bassetti M. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study-authors' response. J Antimicrob Chemother. 2015; 70: 2922.
13. Economics T. Indian Average Daily Wage Rate. Available at: http://www.tradingeconomics.com. 2016. Accessed April 4, 2016.
14. Yigit H Queenan AM Anderson GJ. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001; 45: 1151 1161.
15. Poirel L Walsh TR Cuvillier V. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011; 70: 119 123.
16. Ellington MJ Kistler J Livermore DM. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother. 2007; 59: 321 322.
17. Dallenne C Da Costa A Decré D. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010; 65: 490 495.
18. Dortet L Poirel L Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int. 2014; 2014: 249856.
19. UNICEF. The State of the World's Children 2014. UNICEF, 2014.
20. Walsh Timothy R WJ Livermore David M Toleman Mark A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011; 11: 355 362.
21. Maltezou HC Kontopidou F Katerelos P. Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children. Pediatr Infect Dis J. 2013; 32: e151 e154.
22. Girmenia C Rossolini GM Piciocchi A; Gruppo Italiano Trapianto Midollo Osseo (GITMO); Gruppo Italiano Trapianto Midollo Osseo GITMO. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015; 50: 282 288.
23. Tan GH Tan TH Goh DY. Risk factors for predicting mortality in a paediatric intensive care unit. Ann Acad Med Singapore. 1998; 27: 813 818.
24. de Freitas A de Fatima M Albuquerque PM Goncalves de Mello MJ Ximenes RA. Risk factors associated with death in children admitted to a paediatric intensive care unit. J Trop Pediatr. 2001; 47: 86 91.
25. Esterly JS Wagner J McLaughlin MM. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother. 2012; 56: 4885 4890.
26. Patel TS Nagel JL. Clinical outcomes of enterobacteriaceae infections stratified by carbapenem MICs. J Clin Microbiol. 2015; 53: 201 205.
27. Zusman O Avni T Leibovici L. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013; 57: 5104 5111.
28. Qureshi ZA Paterson DL Potoski BA. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56: 2108 2113.
29. Hsu AJ Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014; 58: 1439 1448.
30. Sick AC Tschudin-Sutter S Turnbull AE. Empiric combination therapy for gram-negative bacteremia. Pediatrics. 2014; 133: e1148 e1155.
31. Thacker N Pereira N Banavali SD. Epidemiology of blood stream infections in pediatric patients at a tertiary care cancer centre. Indian J Cancer. 2014; 51: 438 441.
32. Nation RL Li J Cars O. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015; 15: 225 234.
33. Garonzik SM Li J Thamlikitkul V. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55: 3284 3294.
34. Agency EM. European Medicines Agency completes review of polymyxin-based medicines. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Polymyxin-31/WC500176333.pdf2014. Accessed April 4, 2016.
35. Agency EM. Annex III Amendments to relevant sections of the summary of product characteristics and the package leaflets. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q=product+characteristics+colistin&btnG=Search&mid=WC0b01ac058004d5c12015. Updated 05.01.2015. Accessed April 4, 2016.
36. Falagas ME Vouloumanou EK Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents. 2009; 33: 503.e1 503.e13.
37. Kumar PP Giri SR Shaikh FA. Safety and efficacy of intravenous colistin in children. Indian Pediatr. 2015; 52: 129 130.
38. Tamma PD Newland JG Pannaraj PS. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J. 2013; 32: 17 22.
39. Purdy J Jouve S Yan JL. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther. 2012; 34: 496 507.e1.
40. Hurtado IC Trujillo M Restrepo A Garcés C Tamayo C Mesa JG. [Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae]. Rev Chilena Infectol. 2012; 29: 317 321.
41. Brandon M Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial. J Clin Microbiol. 2013; 51: 2371 2378.
42. Dara JS Chen L Levi MH. Microbiological and genetic characterization of carbapenem-resistant Klebsiella pneumoniae isolated from pediatric patients. J Pediatric Infect Dis Soc. 2014; 3: e10 e14.
43. Iosifidis E Violaki A Michalopoulou E. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant Gram-negative bacteria. J Pediatric Infect Dis Soc. 2016. doi: 10.1093/jpids/piw009.
44. Liu YY Wang Y Walsh TR. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2015. doi: 10.1016/S1473-3099(15)00424-7.
45. Walia K Ohri VC Mathai D; Antimicrobial Stewardship Programme of ICMR. Antimicrobial stewardship programme (AMSP) practices in India. Indian J Med Res. 2015; 142: 130 138.